This study is designed to investigate the movement of insulin NNC0363-0845 throughout the body and how it works for the treatment of type 1 diabetes mellitus.
The aim of the study is to improve clinical outcomes for patients with type 1 diabetes mellitus by better controlling the blood sugar levels.
Participants will get insulin NNC0363-0845 as well as insulin detemir (Levemir®). NNC0363-0845 is a new insulin molecule designed to provide blood sugar-dependent insulin action, while insulin detemir is commonly used and prescribed by doctors.
Participants will get subcutaneous (under your skin) injections of insulin NNC0363-0845 (study medicine) up to 6 times daily for 3 days, and of insulin detemir up to 6 times daily for another 3 days. Which medication participants receive first and which second, insulin NNC0363-0845 or insulin detemir, is decided by chance.
The study will last for about 6 weeks up to a maximum of 14 weeks. Participants will have 2 in-house visits (where participants will stay at the site for 4 nights) and 5 outpatient visits with the study doctor. Participants will have frequent contact with the study doctor during the study.
During the in-house visits, two intravenous catheters (a thin tube inserted into a vein) will be inserted for blood sampling and infusions.
Interested parties may not participate in the study if the study doctor believes it will affect their health negatively.
Women cannot take part if they are of childbearing potential.

Start Date01 Dec 2021

Sponsor / Collaborator

Novo Nordisk A/S

NCT03960814

/ CompletedNot Applicable

Retrospective Cohort Study of All-Cause and Cardiovascular Mortality in Type 2 Diabetes Patients Using Basal Insulin Detemir and Glargine

This study will examine the influence of the basal insulins detemir and glargine on risk of cardiovascular death and death from all causes in patients treated by their general practitioner in United Kingdom (UK). The data for this study will be drawn from the Clinical Practice Research Datalink (CPRD) Register.

Start Date21 May 2019

Sponsor / Collaborator

Novo Nordisk A/S

100 Clinical Results associated with Insulin detemir

100 Translational Medicine associated with Insulin detemir

100 Patents (Medical) associated with Insulin detemir

1,037

Literatures (Medical) associated with Insulin detemir

10 Sep 2024·Clinical diabetes and endocrinology

Long-term TNF-alpha therapy for preserving beta cell function in new onset type 1 diabetes: a case report.

Article

Author: Quinn, Lauren M ; Rao, Adya ; Narendran, Parth

BACKGROUNDType 1 diabetes mellitus (T1D) is an autoimmune disease caused by destruction of pancreatic islet beta-cells. There is significant residual beta-cell function, measured through circulating C-peptide, present at the time of T1D diagnosis but this subsequently decreases with time. Higher residual beta-cell function at diagnosis associates with better glycaemic control and less glucose variability, and later in the disease course with less hypoglycaemia, lower glucose variability and fewer microvascular complications. There is therefore value in preserving residual beta cell function in new onset T1D Immunotherapeutic agents can protect residual beta-cell function in type 1 diabetes. However, clinical trials of such agents, whilst demonstrating C-peptide preservation in short term studies, have yet to be taken forward into routine clinical care due to concerns around safety and long-term efficacy. Here we report the case of a gentleman with newly diagnosed T1D whose glycaemic control and insulin requirement improved whilst on a five year infusion programme of infliximab, a monoclonal antibody against TNF-alpha, for colitis.CASE PRESENTATIONA 52-year-old White Caucasian man was diagnosed with T1D in August 2018. Glucose was 25.6 mmol/L, HbA1c was 98mmol/mol and GAD antibodies were strongly positive. HbA1c marginally improved to 91mmol/mol following initiation of insulin detemir 5 units at night and 1:10 g of insulin aspart (November 2018). In June 2019, he developed rectal bleeding and abdominal pain. Following colonoscopy, he was diagnosed with "indeterminate colitis" and commenced on 6-weekly infusions of 400-450 mg infliximab. Thus far, he has received 32 doses and achieved colitis remission. Following infliximab initiation there was increased frequency of mild-moderate hypoglycaemia and he was gradually weaned off and discontinued detemir in June 2020. Since then, HbA1c improved from 57mmol/mol in August 2019 to 52mmol/mol in April 2022, remaining stable at 51mmol/mol. His most recent HbA1c is 54mmol/mol in February 2024. His c-peptide was 550pmol/L in October 2022 and 442pmol/L in February 2024, suggesting well-preserved beta-cell function almost 6 years post-diagnosis.CONCLUSIONSOur patient's improvement in glycaemic control can be explained by immunomodulation and C peptide preservation from infliximab. With the growing focus on type 1 diabetes disease modulation and working towards an 'insulin free T1D', our findings strengthen the evidence base for the repurposing of and long-term treatment with anti-TNF-α agents to preserve beta-cell function in new onset T1D.

01 Sep 2024·Journal of Diabetes Science and Technology

Regulatory Verification by Health Canada of Content in Recombinant Human Insulin, Human Insulin Analog, and Porcine Insulin Drug Products in the Canadian Market Using Validated Pharmacopoeial Methods Over Nonvalidated Approaches

Article

Author: Rosu-Myles, Michael ; Klein, Agnes V. ; Loo, Shih-Miin ; Lu, Huixin ; Green, Nancy ; Girard, Michel ; Walrond, Lisa ; Zhang, Xu ; Lorbetskie, Barry ; Sauvé, Simon ; Bigelow, Stewart

Background: For diabetes mellitus treatment plans, the consistency and quality of insulin drug products are crucial for patient well-being. Because biologic drugs, such as insulin, are complex heterogeneous products, the methods for drug product evaluation should be carefully validated for use. As such, these criteria are rigorously evaluated and monitored by national authorities. Consequently, reports that describe significantly lower insulin content than their label claims are a concern. This issue was raised by a past publication analyzing insulin drug products available in Canada, and, as a result, consumers and major patient organizations have requested clarification. Methods: To address these concerns, this study independently analyzed insulin drug products purchased from local Canadian pharmacies—including human insulin, insulin analogs, and porcine insulin—by compendial and noncompendial reversed-phase high-performance liquid chromatography (RP-HPLC) methods. Results: We demonstrated the importance of using methods fit for purpose when assessing insulin quality. In a preliminary screen, the expected insulin peak was seen in all products except two insulin analogs—insulin detemir and insulin degludec. Further investigation showed that this was not caused by low insulin content but insufficient solvent conditions, which demonstrated the necessity for methods to be adequately validated for product-specific use. When drug products were appropriately assessed for content using the validated type-specific compendial RP-HPLC methods for insulin quantitation, values agreed with the label claim content. Conclusions: Because insulin drug products are used daily by over a million Canadians, it is important that researchers and journals present data using methods fit for purpose and that readers evaluate such reports critically.

01 Aug 2024·Die Pharmazie

Optimization of a mass spectrometric analytical method for the quality assessment of insulin and its analogs.

Article

Author: Pajaziti, B A ; Kemlendi, N ; Pajaziti, B ; Andrási, M ; Nebija, D

The principal aim of this study was to optimize analytical methodology based on mass spectrometry for the evaluation of the quality of recombinant human insulin and its analogs. In this study ESI-MS was used to assess the quality of human insulin, short acting insulin analogs, insulin lispro, insulin aspart and insulin glulisine and long acting analogs including insulin glargine, insulin degludec, and insulin detemir, in respective pharmaceutical formulations. In this study, with the aimed to optimize analytical conditions, different factors influencing the analytical performance such as pH, ionic strength, sample dilution, organic solvent addition were addressed. The study results demonstrated that MS is a suitable technique for the analysis of biotechnological compounds like insulin and its analogs. Although the obtained results provide an important information regarding this methodology, further studies are needed to validate this analytical approach and check for its suitability to be used in the regulatory environment.

News (Medical) associated with Insulin detemir

08 Jan 2025

·www.echemi.com

80 batches of drugs recalled urgently! A major decision by the National Medical Products Administration

Recently, the National Medical Products Administration announced an important decision to stop the production, sale, and use of Hyoscine Butylbromide Tablets, and to revoke its drug registration certificate. According to the announcement issued by the National Medical Products Administration on January 3, titled “Announcement on the Revocation of the Drug Registration Certificate for Hyoscine Butylbromide Tablets (2025 No. 2)”, Hyoscine Butylbromide Tablets, an antibacterial drug also known as Loperamide, will no longer circulate in the market of our country. This decision is effective immediately, and the products already on the market will be recalled by the marketing authorization holder and supervised by provincial drug regulatory authorities for destruction or other harmless disposal measures. A total of 80 batches of Hyoscine Butylbromide Tablets are involved. In addition, in another announcement issued by the National Medical Products Administration on December 2, 2024, it was also announced that 58 drug registration certificates, including 11 batches of Hyoscine Butylbromide Tablets, have been revoked. Based on Article 83 of the Drug Administration Law of the People's Republic of China and other relevant regulations, these drugs have been required to stop production and sale due to unclear efficacy, serious adverse reactions, or other hazards to human health. Hyoscine Butylbromide Tablets are a compound preparation, with the main active ingredients including Hyoscine Tincture, Sulfamethoxazole, and Trimethoprim, primarily used to treat dysentery caused by Shigella and other sensitive pathogenic bacteria causing enteritis. However, with the withdrawal of this drug from the market, other drugs such as Montmorillonite Powder will take on the responsibility for treating diarrhea. According to data from Miiine, the incidence of gastrointestinal diseases is on the rise and is becoming more prevalent among younger populations. In the first three quarters of 2022, the sales of anti-diarrheal drugs and intestinal anti-inflammatory/infection drugs in public hospitals in key provinces and cities in China exceeded 1.2 billion yuan, a year-on-year increase of 6.30%. The sales scale of Montmorillonite Powder in the three major terminal markets in China has exceeded 1 billion yuan, with the outpatient market being the main sales channel, rising by 60%, making it the Top 2 product in anti-diarrheal and intestinal anti-inflammatory/infection drugs. Statistics from Cyborg Blue show that 145 drug registration certificates were revoked in 2024. In the announcement on December 2, 2024, in addition to Hyoscine Butylbromide Tablets, it also included 3 batches of Losartan Potassium Tablets, 2 batches of Phenazone Tablets, 2 batches of Amlodipine Besylate Tablets, 2 batches of Entecavir Tablets, 2 batches of Compound Snake Gall and Chuan Bei Powder, and 2 batches of Rifampicin Capsules. Phenazone, as a pyrazolone analgesic and antipyretic, was launched early in our country, but its injection and nasal drops have severe adverse reactions, with risks outweighing benefits, and alternative medications are available, leading to its registration certificate being revoked in 2020. Although oral preparations like Phenazone Tablets still have certain clinical value, the National Medical Products Administration has implemented risk control measures by revising the instructions to add safety warnings, restricting applicable populations and indications. In the domestic market for antipyretic and analgesic drugs, Phenazone has a low market share and is declining. Data from Cyborg Blue shows that there are 861 approvals for "Phenazone Tablets," involving many companies and intense market competition. As related drug approvals are revoked, this market will face further fragmentation. Finally, according to the relevant provisions of the Regulations on the Implementation of the Drug Administration Law of the People's Republic of China and the Drug Registration Management Measures, the National Medical Products Administration decided on April 11, 2024, to revoke the registration certificates for 87 drugs, including Pancreatin Injection. Cyborg Blue’s analysis found that drugs such as 7 batches of Iohexol Injection, 6 batches of Insulin Glargine Injection, 4 batches of Detemir Insulin Injection, 4 batches of Vardenafil Hydrochloride Tablets, and 3 batches of Brain Protein Hydrolysate Injection were also revoked. Please note that the number of drugs counted in the text has not been deduplicated. No. Marketing Authorization Holder Approval Number 1 Shijiazhuang Lesheng Pharmaceutical Co., Ltd. SFDA H13023949 2 Jiangzhong Pharmaceutical Co., Ltd. SFDA H36022316 3 Shijiazhuang Fourth Pharmaceutical Co., Ltd. SFDA H13023932 4 Shijiazhuang Grey Pharmaceutical Co., Ltd. SFDA H13023934 5 Handan Bailin Pharmaceutical Co., Ltd. SFDA H13023945 6 Hebei Yongfeng Pharmaceutical Co., Ltd. SFDA H13023943 7 China National Pharmaceutical Group Wuhan Zhonglian Fourth Pharmaceutical Co., Ltd. SFDA H42022497 8 Jiangsu Enhua Pharmaceutical Co., Ltd. SFDA H32025932 9 Jiangxi Hongshuo Pharmaceutical Co., Ltd. SFDA H36022013 10 Jiangxi Hongshuo Pharmaceutical Co., Ltd. SFDA H36022244 11 Jiangsu Chenpai Pharmaceutical Group Co., Ltd. SFDA H32025935 12 North China Pharmaceutical Hebei Huanuo Co., Ltd. SFDA H13024102 13 North China Pharmaceutical Hebei Huanuo Co., Ltd. SFDA H13024073 14 Hebei Hengli Group Pharmaceutical Co., Ltd. SFDA H13024253 15 Hebei Tianzhi Pharmaceutical Co., Ltd. SFDA H13024245 16 Hebei Dongfeng Pharmaceutical Co., Ltd. SFDA H13024170 17 Hebei Jinzhuan Pharmaceutical Co., Ltd. SFDA H13024269 18 Tianjin Baihai Pharmaceutical Co., Ltd. SFDA H12021099 19 Henan Daxin Pharmaceutical Co., Ltd. SFDA H41024876 20 Henan Daxin Pharmaceutical Co., Ltd. SFDA H41025013 21 Shanxi Xinxing Pharmaceutical Co., Ltd. SFDA H14023068 22 Jiangxi Jiminke Pharmaceutical Co., Ltd. SFDA H36022305 23 Suzhou Hongsun Pharmaceutical Co., Ltd. SFDA H32025897 24 Jiangsu Puhua Kesheng Pharmaceutical Co., Ltd. SFDA H32026256 25 Guangxi Tiantianle Pharmaceutical Co., Ltd. SFDA H45021319 26 Tianjin Central Pharmaceutical Co., Ltd. SFDA H12021120 27 Tianjin Central Pharmaceutical Co., Ltd. SFDA H12021117 28 Shanghai Modern Harsen (Shangqiu) Pharmaceutical Co., Ltd. SFDA H41024989 29 Tianjin Pacific Pharmaceutical Co., Ltd. SFDA H12021100 30 Hebei Guojin Pharmaceutical Co., Ltd. SFDA H13023940 31 Hebei Kaiwei Pharmaceutical Co., Ltd. SFDA H13023920 32 Hebei Sanshi Pharmaceutical Co., Ltd. SFDA H13023928 33 Yuanda Pharmaceutical (China) Co., Ltd. SFDA H42022649 34 Shanxi Tongda Pharmaceutical Co., Ltd. SFDA H14023309 35 Shanxi Guorun Pharmaceutical Co., Ltd. SFDA H14023402 36 Shanxi Fenhe Pharmaceutical Co., Ltd. SFDA H14023200 37 Shanxi Wanhui Pharmaceutical Co., Ltd. SFDA H14023333 38 Jilin Wantong Pharmaceutical Co., Ltd. SFDA H22025288 39 Changchun Overseas Pharmaceutical Group Co., Ltd. SFDA H22026726 40 Shijiazhuang Xiehe Pharmaceutical Co., Ltd. SFDA H13024084 41 Shandong Xinyi Pharmaceutical Co., Ltd. SFDA H37023541 42 Kuihua Pharmaceutical Group (Hengshui) Defier Co., Ltd. SFDA H13023979 43 Shijiazhuang Kanghewai Pharmaceutical Co., Ltd. SFDA H13024261 44 Shandong Xinhua Pharmaceutical Co., Ltd. SFDA H37023523 45 Hebei Yuzhilin Pharmaceutical Co., Ltd. SFDA H13024426 46 Xinhai Yansheng Pharmaceutical Co., Ltd. SFDA H41024907 47 Fu'an Pharmaceutical Group Yantai Zhichu Pharmaceutical Co., Ltd. SFDA H37023543 48 Dingfukang Pharmaceutical Co., Ltd. SFDA H41025139 49 Dingfukang Pharmaceutical Co., Ltd. SFDA H41025174 50 Changchun Changqing Pharmaceutical Group Co., Ltd. SFDA H22025234 51 Henan Baiquan Pharmaceutical Co., Ltd. SFDA H41024840 52 Changzhou Kangpu Pharmaceutical Co., Ltd. SFDA H32025910 53 Henan Baiquan Pharmaceutical Co., Ltd. SFDA H41025575 54 Lepu Hengjiuyuan Pharmaceutical Co., Ltd. SFDA H41024862 55 Hebei Ruicen Pharmaceutical Co., Ltd. SFDA H13023953 56 Hainan Xiansheng Pharmaceutical Co., Ltd. SFDA H46020588 57 Hainan Xiansheng Pharmaceutical Co., Ltd. SFDA H46020604 58 Yaodu Pharmaceutical Group Co., Ltd. SFDA H13023951 59 Shandong Xinyi Pharmaceutical Co., Ltd. SFDA H37023939 60 Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Co., Ltd. SFDA H13023952 61 Tianfang Pharmaceutical Co., Ltd. SFDA H41024887 62 Lepu Hengjiuyuan Pharmaceutical Co., Ltd. SFDA H41025576 63 Zhejiang Huisong Pharmaceutical Co., Ltd. SFDA H33022412 64 Zhejiang Huisong Pharmaceutical Co., Ltd. SFDA H33022411 65 Shanghai Kaibao Xinyi (Xinxiang) Pharmaceutical Co., Ltd. SFDA H41024834 66 Henan Xueyinghua Pharmaceutical Co., Ltd. SFDA H41024896 67 Henan Xueyinghua Pharmaceutical Co., Ltd. SFDA H41025009 68 Shijiazhuang Pharmaceutical Group Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. SFDA H13023994 69 Handan Furong Pharmaceutical Co., Ltd. SFDA H13024077 70 Hebei Tiancheng Pharmaceutical Co., Ltd. SFDA H13024056 71 Hebei Kangtai Pharmaceutical Co., Ltd. SFDA H13024041 72 Guangdong Bidi Pharmaceutical Co., Ltd. SFDA H44025328 73 Guangdong Bidi Pharmaceutical Co., Ltd. SFDA H44024963 74 Zhengzhou Furuitang Pharmaceutical Co., Ltd. SFDA H41025579 75 Chongqing Kerui Pharmaceutical (Group) Co., Ltd. SFDA H50021730 76 Baiyun Mountain Dongtai Shangqiu Pharmaceutical Co., Ltd. SFDA H41024872 77 Xinxiang Changle Pharmaceutical Co., Ltd. SFDA H41024895 78 Xinxiang Changle Pharmaceutical Co., Ltd. SFDA H41025012 79 Baiyun Mountain Dongtai Shangqiu Pharmaceutical Co., Ltd. SFDA H41025008 80 Tianfang Pharmaceutical Co., Ltd. SFDA H41025010

Drug ApprovalNDA

27 Sep 2024

·endpts.com

Novo Nordisk to decrease some insulin pen manufacturing, transition supply

Novo Nordisk has told government and global nonprofits that it plans to significantly downsize its manufacturing of some of its insulin pens, according to one of the groups, and will transition a portion of its global supply to insulin vials and syringes that are easier to make but less convenient for patients. The company’s plans were disclosed in recent discussions with Doctors Without Borders, who described them to Endpoints News , as well as the WHO, the Australian government, and other governments and regulators. “We are not halting production of insulin in pens,” Novo said in an email to Endpoints. “In some cases, we will no longer make human insulin available in pens. It will be made available in a vial and disposable syringe.” While some countries, like Australia and South Africa, are now seeking alternatives, the full extent of Novo’s plans isn’t immediately clear. The company declined to comment further to Endpoints on exactly which markets would be affected. And it said that some — but not all — insulin pens would be affected by the shift. And it emphasized that the changes would happen slowly, over a period of years. While South Africa in June announced shortages of insulin pens due to Novo’s decision to deprioritize their manufacture and supply, Doctors Without Borders’ pharmacist coordinator Christina Cepuch told Endpoints Friday that the latest announcement would go much further, based on the company’s comments to the groups. Geneva-based Doctors Without Borders is also known as Médecins Sans Frontières, or MSF. The WHO lists Novo’s insulin pens on its essential medicines list , and will also have to find alternatives, Cepuch said. The WHO did not immediately respond to a request for comment. “What does the WHO do about this? There’s not going to be any left. I mean, Lilly makes these, but they don’t make large volumes,” Cepuch said. “And what is WHO going to tell member states? Change everyone to glargine pens or go back to vials?” Glargine is a form of long-acting insulin, and Novo is currently in the process of phasing out its own long-acting insulin, called Levemir. On Tuesday, the Therapeutic Goods Administration, Australia’s drug regulator, released a short notice saying Novo will discontinue “some of its earlier generation insulin products” over the next two years. Scant on details, the notice said Australia is looking into alternatives. Novo emphasized to Endpoints that it is expanding its overall drug manufacturing significantly with the acquisition of Catalent and other new investments. Earlier this week, the Danish company’s CEO Lars Fruergaard Jørgensen testified before the US Senate at a hearing on drug prices and was asked by Sen. Tammy Baldwin (D-WI) about its insulin manufacturing plans. Baldwin asked Jørgensen if he would commit to “continue to have a focus on providing critical insulin. You will not reduce your manufacturing capacity in that area.” “The world market for insulin is actually declining, so there’s less demand,” Jørgensen responded. “But we are committed to supply to the patient that has been using our insulin for years also into the future.” Cepuch suggested that the company might decide to use freed-up pen capacity for its GLP-1 obesity products, which are also in shortage, or other insulins. Novo said the insulin and GLP-1 pens are different.

24 Sep 2024

·www.fiercepharma.com

With Novo CEO on the hot seat at Senate hearing, PBMs and insurance concerns get the spotlight

Committee chair Sen. Bernie Sanders, I-Vermont, initially threatened to subpoena Novo Nordisk's CEO Lars Fruergaard Jørgensen to ensure his appearance at the hearing. When government officials and politicians scrutinize high U.S. drug prices, the role of insurers and pharmacy benefit managers (PBMs) often commands at least some of the attention.Tuesday, the Senate Health, Education, Labor and Pensions (HELP) Committee's hearing on Ozempic and Wegovy prices, which featured Novo Nordisk's CEO Lars Fruergaard Jørgensen as the sole witness, was no different. In his opening remarks, committee chair Sen. Bernie Sanders, I-Vermont, angled to dismantle Jorgensen's PBM-related defense by revealing a written commitment from the nation's three largest insurers that they would not limit coverage if Novo were to cut the list prices of its massively popular GLP-1 drugs. Cigna Group, CVS Health and UnitedHealth, which together comprise the majority of the commercial insurance market, each confirmed that lowered prices would not adversely affect patient access through their respective programs. The insurers each operate large PBM divisions.As it stands, PBMs receive bigger rebates on drugs with higher costs, a dynamic that can result in lower-priced drugs being placed lower on formularies or dropped altogether from the coverage lists. Last year, the HELP committee proposed a bipartisan PBM reform bill that has yet to pass to the Senate floor.At the hearing, Jorgenson expressed “a bit of concern” for how Ozempic and Wegovy price cuts could play out on the PBM side, citing prior experience with Novo’s insulin Levemir being removed from formularies after a price cut. But the CEO said he'd "be happy to” sit down with the PBMs and discuss options.“I understand that perhaps the PBMs have changed their mind, and I'll be happy to collaborate with them on this, because anything that helps patients to get access and affordability, we are supportive of,” he added. Jørgensen’s concern was in reference to its recent experience with the long-acting insulin Levemir, which will be discontinued by the end of this year due in part to formulary concerns, Novo has said. The move came after the insulin maker agreed to slash Levemir’s price by 65%.“We dropped the price, yet to find that PBMs dropped access to Levemir, so much less patients have access to it,” Jørgensen said.Still, throughout the hearing, the CEO reiterated his support of working with the PBMs. As for what happens next, Jørgensen is less certain, but he agreed that the company is open to lowering prices “if it works in a way where patients get access to a more affordable medicine, and we have certainty that it actually happens.”"Our hope is that the conversation with the HELP Committee will result in real and tangible solutions that benefit patients and allow millions of people living with these serious and chronic diseases to be the direct beneficiaries of real change,” Novo said in an emailed statement following the hearing.

100 Deals associated with Insulin detemir

External Link

KEGG	Wiki	ATC	Drug Bank
D04539	Insulin detemir	A10AE05	DB01307

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	US	Novo Nordisk A/S	19 Oct 2005
Diabetes Mellitus, Type 2	US	Novo Nordisk A/S	19 Oct 2005
Diabetes Mellitus	EU	Novo Nordisk A/S	01 Jun 2004
Diabetes Mellitus	LI	Novo Nordisk A/S	01 Jun 2004
Diabetes Mellitus	IS	Novo Nordisk A/S	01 Jun 2004
Diabetes Mellitus	NO	Novo Nordisk A/S	01 Jun 2004

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 1	Phase 2	SE	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	BE	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	AU	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	GB	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	DK	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	NL	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	IE	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	FR	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	FI	Novo Nordisk A/S	01 Feb 2001
Diabetes Mellitus, Type 1	Discovery	NO	Novo Nordisk A/S	01 Feb 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01186003 (CTgov)	Not Applicable	Diabetes Mellitus	30	insulin+detemir (Standard Insulin Drip Therapy)	jbshqknwvg(kexijwcdvb) = tyuoqslyhk inucmdaslv (bdumbajugh, kcegpyetwd - elbqblwaui) View more	-	07 Dec 2021
				Detemir (Insulin Drip and Detemir)	jbshqknwvg(kexijwcdvb) = ykteiykabt inucmdaslv (bdumbajugh, cidivvlwpk - bxsfvugiuw) View more
NCT03377699 (EXPECT, EASD2021)	Phase 3	Diabetes Mellitus, Type 1	225	Degludec	(srrxcazzps) = kbdrdymsdk qkdoadokwj (dgbfkrkpjj, -0.11)	Positive	28 Sep 2021
				Detemir	(srrxcazzps) = bcsuhelobh qkdoadokwj (dgbfkrkpjj )
NCT03620890 (Determin, CTgov)	Phase 4	Diabetes Mellitus, Type 2	108	Detemir insulin (Detemir)	pplhnuxzjk(ladhtedgdu) = rvjzyxcvry zsbrpglarc (gaxdmcmfja, tiqqpgimfo - nnokczrqsk) View more	-	18 Aug 2021
				Neutral Protamine Hagedorn (NPH) (Neutral Protamine Hagedorn (NPH))	pplhnuxzjk(ladhtedgdu) = qjxrecmzkk zsbrpglarc (gaxdmcmfja, ijazuzvqtv - yybmittjys) View more
NCT02846233 (CTgov)	Not Applicable	Diabetes Mellitus, Type 2	22	SGLT2 inhibitor+levemir+Lantus+Metformin (Treatment Group)	bmnabesmsp(yazdtpqxpz) = nffeylgaqu ppmudweekc (uibbsgiiga, aszluuuvew - kcttuezckz) View more	-	10 Nov 2020
				SGLT2i (Control Group)	bmnabesmsp(yazdtpqxpz) = vagmdranlm ppmudweekc (uibbsgiiga, wojavwbpll - wmsxxbdopy) View more
NCT01966978 (SIMPLE, CTgov)	Phase 4	Diabetes Mellitus, Type 2	157	Insulin Aspart+Detemir+Metformin (Control: Metformin, Insulin Detemir, Insulin Aspart)	yeylfvbhua(rduntbekzb) = ssrabzgrsq dorjpvafmx (iaysxtloyv, tuvpuyxudk - ixcmyizvpl) View more	-	22 Oct 2019
				Detemir+liraglutide+Metformin (Metformin, Insulin Determir, Liraglutide)	yeylfvbhua(rduntbekzb) = bvveapyfcf dorjpvafmx (iaysxtloyv, vbyheouydq - lcdxhwbfwz) View more
NCT00564018 (CTgov)	Not Applicable	Diabetes Mellitus, Type 1	33	Insulin detemir (Detemir)	bpsorzqecn(usjxbgkcrj) = vrgcpgrkbt nnvdqarfwz (nyuxgyjlul, pkzsscnbxq - wbenyharxo) View more	-	11 Oct 2019
				glargine (Glargine)	bpsorzqecn(usjxbgkcrj) = gwsoorozdm nnvdqarfwz (nyuxgyjlul, dlothesvrn - gbiugipzpm) View more
NCT01232946 (CTgov)	Not Applicable	Diabetes Mellitus, Type 2	30	liraglutide (Iiraglutide)	bhmmclhliq(nmznhwroim) = bpnwmxqqlf pcxutiatap (nxzexdfote, edvjzebsuq - wcntnbikym) View more	-	07 Aug 2019
				Insulin detemir (Insulin Detemir)	bhmmclhliq(nmznhwroim) = omobkvxtbk pcxutiatap (nxzexdfote, fhyjgoqanu - bqitlgteqi) View more
NCT00639626 (CTgov)	Phase 2/3	Cystic fibrosis related diabetes	6	insulin detemir [rDNA origin] injection	legswpwmev(seyddzijnc) = cvjpzumgyf nzvtbaabar (cjswohktif, rfrfrxpliu - clpxxqxvgj) View more	-	12 Apr 2018
NCT01595646 (SL120, CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	37	Saline (Saline)	jeaqsksbhf(gcybbvhodj) = jgkcciuxvd ubplnonlgz (dxthdwdrij, xoeuenynpp - xinngnhxlo) View more	-	01 Feb 2018
				Insulin detemir (Insulin Detemir)	jeaqsksbhf(gcybbvhodj) = ctgtdzlqet ubplnonlgz (dxthdwdrij, rfvjnizfgr - ozcdtkxykc) View more
NCT01850615 (onset® 3 \| onset ® 3 \| onset 3, CTgov)	Phase 3	Diabetes Mellitus, Type 2	323	NPH insulin+insulin detemir+metformin+aspart (Faster Aspart + Basal)	gqkaddxvcd(uxdynfntto) = youdhdslqi wxgcpawtvc (tppxxaurxs, ydaervcxkf - zwingyqyuh) View more	-	17 Jan 2018
				NPH insulin+insulin detemir+metformin (Basal)	gqkaddxvcd(uxdynfntto) = hrtwmxzric wxgcpawtvc (tppxxaurxs, wmtmejffib - xmlidvciwp) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis